Table 3.
Serum levels of LDH, CK-MB, cTn-I, AST, and ALT 12 days after treatment (n = 6).
| Ctrl | DOX | Api + DOX | DOX + Api-AuNPs | |
|---|---|---|---|---|
| LDH (IU/L) | 578.9 ± 39.48 | 1139 ± 78.09**** | 714.4 ± 41.49#### | 733.7 ± 54.08### |
| CK-MB (ng/ml) | 0.255 ± 0.018 | 0.51 ± 0.03**** | 0.32 ± 0.016#### | 0.355 ± 0.019*### |
| cTn-I (ng/ml) | 0.6733 ± 0.044 | 3.475 ± 0.273**** | 1.035 ± 0.069#### | 1.015 ± 0.08512#### |
| AST (IU/L) | 84.14 ± 4.964 | 131.6 ± 10.18** | 99.29 ± 9.426 | 91.86 ± 9.47# |
| ALT (IU/L) | 43.71 ± 3.53 | 70.14 ± 5.535** | 48.00 ± 2.92## | 46.14 ± 4.61## |
Data are presented as Mean ± SEM. LDH; lactate dehydrogenase, CK-MB; Creatine kinase-MB, cTn-I; cardiac troponin I, AST; aspartate aminotransferase, ALT; alanine aminotransferase, DOX; Doxorubicin, Api; Apigenin, and Api-AuNPs; Apigenin coated gold nanoparticles.
**P < 0.01, ***P < 0.001 and ****P < 0.0001, vs. ctrl group and #P < 0.05, ##P < 0.01, ###P < 0.001 and ####P < 0.0001 vs. DOX group.